Dupixent Growth Sparks Buzz: Recent chatter on social media about Regeneron Pharmaceuticals has centered on the strong performance of Dupixent, their flagship drug for allergic conditions. Many users are highlighting the drug’s consistent revenue growth as a key driver for the stock’s potential. Discussions also note upcoming pipeline catalysts expected in 2026 as a point of interest.
Pipeline and Partnerships in Focus: Another hot topic involves Regeneron’s strategic moves, including a $120 million investment in a small molecule development partnership. Social media conversations reflect curiosity about how these efforts, alongside drugs like Fianlimab for melanoma, could shape future growth. The tone suggests optimism about the company’s innovation despite some concerns over competitive pressures.
Note: This discussion summary was generated from an AI condensation of post data.
Regeneron Pharmaceuticals Insider Trading Activity
Regeneron Pharmaceuticals insiders have traded $REGN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:
- CHRISTINE A POON has made 0 purchases and 6 sales selling 6,500 shares for an estimated $4,252,745.
- BONNIE L BASSLER sold 760 shares for an estimated $570,000
- JASON PITOFSKY (VP Controller) sold 431 shares for an estimated $280,766
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenues of $3.8B in Q3 2025. This is an increase of 0.9% from the same period in the prior year.
You can track REGN financials on Quiver Quantitative's REGN stock page.
Regeneron Pharmaceuticals Congressional Stock Trading
Members of Congress have traded $REGN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/18.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Regeneron Pharmaceuticals Hedge Fund Activity
We have seen 654 institutional investors add shares of Regeneron Pharmaceuticals stock to their portfolio, and 685 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 2,288,699 shares (-72.3%) from their portfolio in Q3 2025, for an estimated $1,286,866,786
- FMR LLC removed 1,391,216 shares (-41.8%) from their portfolio in Q3 2025, for an estimated $782,239,020
- DODGE & COX added 724,562 shares (+18.9%) to their portfolio in Q3 2025, for an estimated $407,399,475
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 627,905 shares (+73.0%) to their portfolio in Q3 2025, for an estimated $353,052,144
- AQR CAPITAL MANAGEMENT LLC added 606,612 shares (+528.7%) to their portfolio in Q3 2025, for an estimated $341,079,729
- CITADEL ADVISORS LLC removed 450,278 shares (-66.2%) from their portfolio in Q3 2025, for an estimated $253,177,811
- BLACKROCK, INC. removed 438,911 shares (-4.7%) from their portfolio in Q3 2025, for an estimated $246,786,487
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Regeneron Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/04/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- HSBC issued a "Buy" rating on 11/24/2025
- B of A Securities issued a "Underperform" rating on 10/29/2025
- Guggenheim issued a "Buy" rating on 10/29/2025
- Citigroup issued a "Buy" rating on 10/29/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/29/2025
To track analyst ratings and price targets for Regeneron Pharmaceuticals, check out Quiver Quantitative's $REGN forecast page.
Regeneron Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 16 analysts offer price targets for $REGN in the last 6 months, with a median target of $775.5.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $768.0 on 12/12/2025
- Mohit Bansal from Wells Fargo set a target price of $745.0 on 12/10/2025
- Evan David Seigerman from BMO Capital set a target price of $850.0 on 12/04/2025
- John Newman from Canaccord Genuity set a target price of $1057.0 on 12/04/2025
- Louise Chen from Scotiabank set a target price of $770.0 on 11/24/2025
- Yifeng Liu from HSBC set a target price of $890.0 on 11/24/2025
- Gregory Renza from Truist Securities set a target price of $798.0 on 11/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
